Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.8% – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL) shares traded down 5.8% during mid-day trading on Tuesday . The stock traded as low as $3.06 and last traded at $3.07. 126,730 shares traded hands during trading, a decline of 91% from the average session volume of 1,458,050 shares. The stock had previously closed at $3.26.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Price Performance

The stock’s 50 day moving average is $3.70 and its two-hundred day moving average is $3.89. The stock has a market capitalization of $811.59 million, a PE ratio of -2.52 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the firm posted ($0.26) EPS. On average, equities analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after purchasing an additional 6,330,392 shares during the last quarter. State Street Corp increased its stake in Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after purchasing an additional 10,401 shares during the last quarter. HighVista Strategies LLC increased its stake in Autolus Therapeutics by 2.7% in the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after purchasing an additional 14,204 shares during the last quarter. Erste Asset Management GmbH purchased a new position in Autolus Therapeutics in the third quarter valued at approximately $708,000. Finally, Bellevue Group AG increased its stake in Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.